Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

2024116 citationsJournal Articlehybrid Open Access

Authors

Fred Saad · Centre Hospitalier de l’Université de Montréal

Egils Vjaters · Pauls Stradiņš Clinical University Hospital

Neal D. Shore · Carolina Urologic Research Center

David Olmos · Hospital Universitario 12 De Octubre

Nianzeng Xing · Chinese Academy of Medical Sciences & Peking Union Medical College

Andrea Juliana Gomes

Augusto César de Andrade Mota

Abstract

These results confirm the efficacy and tolerability of darolutamide plus ADT in patients with mHSPC, demonstrating clinically and statistically significant improvement in rPFS and a favorable safety profile consistent with prior phase III darolutamide trials.

Topics & Keywords

Prostate Cancer Treatment and Research Hormonal and reproductive studies Cancer, Lipids, and Metabolism

Publication Details

Published in: Journal of Clinical Oncology

Volume 42, Issue 36, pp. 4271-4281

DOI: 10.1200/jco-24-01798

Field-Weighted Citation Impact: 48.16

Command Palette

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Authors

Abstract

Topics & Keywords

Publication Details